Literature DB >> 23759507

Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery.

C H Chilton1, J Freeman, S D Baines, G S Crowther, S Nicholson, M H Wilcox.   

Abstract

OBJECTIVES: Previous work suggests oritavancin may be inhibitory to Clostridium difficile spores. We have evaluated the effects of oritavancin exposure on C. difficile spore germination, outgrowth and recovery.
METHODS: Germination and outgrowth of C. difficile spores exposed to different concentrations of oritavancin, vancomycin, or metronidazole (0.1-10 mg/L) were monitored at 0, 2, 4, 6, 24 and 48 h using phase-contrast microscopy. Recovery of antimicrobial-exposed spores was determined by viable counting on Brazier's modified CCEYL agar. Persistence of oritavancin activity on spores after washing was determined by measuring activity against a Staphylococcus aureus lawn.
RESULTS: Oritavancin, vancomycin and metronidazole exposure did not prevent germination of phase-bright spores to phase-dark spores, but did inhibit further outgrowth into vegetative cells. The inhibitory effect of oritavancin persisted after washing, whereas the inhibitory effects of vancomycin and metronidazole did not. Oritavancin exposure affected spore recovery; fewer spores were recovered after washing following oritavancin exposure than vancomycin exposure. The extent of this effect was dependent on PCR ribotype, with recovery of ribotype 078 spores completely prevented, but recovery of ribotype 001 spores only slightly affected. Spores exposed to oritavancin, but not vancomycin, retained antimicrobial activity after washing, indicating adherence of oritavancin, but not vancomycin, to the spore surface
CONCLUSIONS: Oritavancin may adhere to spores, potentially causing early inhibition of germinated cells, preventing subsequent vegetative outgrowth and spore recovery. This may prevent some recurrences of symptomatic C. difficile infection that are due to germination of residual spores following antibiotic therapy.

Entities:  

Keywords:  adherence; outgrowth inhibition; recurrence

Mesh:

Substances:

Year:  2013        PMID: 23759507     DOI: 10.1093/jac/dkt160

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  Detecting Clostridium difficile spores from inanimate surfaces of the hospital environment: which method is best?

Authors:  Tânia Claro; Stephen Daniels; Hilary Humphreys
Journal:  J Clin Microbiol       Date:  2014-07-09       Impact factor: 5.948

2.  Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin.

Authors:  Daniela Münch; Ina Engels; Anna Müller; Katrin Reder-Christ; Hildegard Falkenstein-Paul; Gabriele Bierbaum; Fabian Grein; Gerd Bendas; Hans-Georg Sahl; Tanja Schneider
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

3.  Factors associated with Clostridium difficile diarrhea in a hospital in Beijing, China.

Authors:  Z Lv; G L Peng; J R Su
Journal:  Braz J Med Biol Res       Date:  2014-09-30       Impact factor: 2.590

4.  Ambush of Clostridium difficile spores by ramoplanin: activity in an in vitro model.

Authors:  Carl N Kraus; Matthew W Lyerly; Robert J Carman
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

5.  A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment.

Authors:  Bradley Endres; Eugénie Bassères; Tasnuva Rashid; Long Chang; M Jahangir Alam; Kevin W Garey
Journal:  J Vis Exp       Date:  2017-05-25       Impact factor: 1.355

Review 6.  Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors:  Françoise Van Bambeke
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

7.  Synthetic polymers active against Clostridium difficile vegetative cell growth and spore outgrowth.

Authors:  Runhui Liu; Jose M Suárez; Bernard Weisblum; Samuel H Gellman; Shonna M McBride
Journal:  J Am Chem Soc       Date:  2014-10-03       Impact factor: 15.419

Review 8.  Clostridium difficile drug pipeline: challenges in discovery and development of new agents.

Authors:  Angie M Jarrad; Tomislav Karoli; Mark A T Blaskovich; Dena Lyras; Matthew A Cooper
Journal:  J Med Chem       Date:  2015-03-30       Impact factor: 7.446

Review 9.  Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.

Authors:  Lissa S Tsutsumi; Yaw B Owusu; Julian G Hurdle; Dianqing Sun
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 10.  Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections.

Authors:  Karrine D Brade; Jeffrey M Rybak; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2016-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.